MetaCap

CapsoVision (CV) vs Hyperfine (HYPR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CapsoVision (CV) has outperformed Hyperfine (HYPR) over the past year, gaining 16.8% versus a loss of 48.0%. CapsoVision is the larger company by market cap ($327.6 million vs $58.0 million), about 5.7 times the size. CapsoVision converts more of its revenue into profit, with a net margin of -186.8% versus -262.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CV+16.83%HYPR-47.95%
+187%+63%-61%
Nov 21, 20251 yearNov 20, 2026
CV+38.86%HYPR-31.69%
+212%+84%-43%
Jun 30, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CV versus HYPR key metrics
MetricCVHYPR
Share price$6.11$0.5465
Market cap$327.56M$57.96M
1-day change-3.17%+4.27%
YTD return-42.84%-44.18%
1-year return+16.83%-47.95%
5-year return—-94.45%
EPS (TTM)$-0.42$-0.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$13.55M$13.56M
Revenue growth (YoY)+15.29%+5.22%
Net income (latest FY)$-25.32M$-35.57M
Gross margin52.92%49.79%
Operating margin-188.25%-273.43%
Net margin-186.77%-262.29%
52-week high$15.37$1.94
52-week low$4.50$0.488
Distance from 52-week high-60.25%-71.76%
Analyst consensusstrong_buynone
Avg. price target upside+55.48%+271.45%
Average volume173.59K760.76K
Shares outstanding53.61M90.99M
Employees99102
SectorHealth CareHealth Care
IndustryBiotechnology: Electromedical & Electrotherapeutic ApparatusBiotechnology: Electromedical & Electrotherapeutic Apparatus

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CapsoVision is about 5.7 times larger than Hyperfine by market value ($327.56M vs $57.96M).
  • CV has outperformed HYPR by 64.8 percentage points over the past year.
  • CapsoVision is more profitable, keeping -186.8 cents of every revenue dollar as net income versus -262.3 cents for Hyperfine.
  • CapsoVision grew revenue faster in its latest fiscal year (+15.29% vs +5.22%).

About CapsoVision

CV stock →

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 99 employees

About Hyperfine

HYPR stock →

Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop Portable MR Imaging System produces images at a lower magnetic field strength than conventional MRI scanners.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 102 employees

CV vs HYPR FAQ

Which is bigger, CapsoVision or Hyperfine?

CapsoVision (CV) is larger, with a market capitalization of $327.56M compared with $57.96M for Hyperfine (HYPR).

Which stock has performed better over the past year, CV or HYPR?

CV returned +16.83% over the past 12 months, compared with -47.95% for HYPR (price return, excluding dividends). Past performance does not predict future results.

Are CapsoVision and Hyperfine in the same industry?

Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.

More comparisons